Werewolf Therapeutics Reports WTX-124 and WTX-330 Clinical Data at SITC 2026

Werewolf Therapeutics presented clinical data for WTX-124 and WTX-330, showing antitumor activity in advanced solid tumors. WTX-124's recommended Phase 2 dose was aligned with the FDA, and it demonstrated durable responses. WTX-330 showed a partial response in a gallbladder cancer patient and was well tolerated.

Original reporting
Published Nov 9, 2026, 2:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 2:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Werewolf Therapeutics Reports WTX-124 and WTX-330 Clinical Data at SITC 2026 — source image
Decision brief

The 30-second read

$HOWLBullishMed
01

Why it matters

The disclosed Phase 1/2 data provide the first efficacy readout for its lead programs, which could materially affect the stock price.

02

Market read

First‑time disclosure of trial outcomes for a micro‑cap biotech, likely to generate short‑term price movement.

03

What to watch

Potential regulatory scrutiny of combination with pembrolizumab and competitive pipeline dynamics.

Relevance 8/10Novelty 8/10Timing: today

Background

Werewolf Therapeutics (HOWL) is a clinical‑stage biotech focused on engineered cytokine therapeutics.

Company-level read

Ticker impact

$HOWLBullishHigh confidence
Context

Werewolf Therapeutics filed an 8‑K reporting new Phase 1/2 clinical data for WTX‑124 and WTX‑330, including dose recommendations and partial responses.

Expected impact

potential upside as traders price in efficacy signals

Evidence & confidence

First disclosure of durable responses and a confirmed partial response provides material new information for a micro‑cap biotech.

Market effects

Early data could boost interest in IL‑12/STAT4 pathway programs across oncology.

Limited to US biotech investors; no broader regional effect.

Modest, confined to specialty oncology investors.

Counterpoint

Data are early‑stage; efficacy may not translate to later trials, risk of disappointment.

Key entities

  • Werewolf Therapeutics, Inc.

    Issuer of the clinical data.

  • WTX-124

    IL-12 cytokine fusion protein evaluated in solid tumors.

  • WTX-330

    IL-12 cytokine fusion protein with partial response observed.

Related articles

$HOWLMedAI 8/10

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou

$HOWLHighAI 8/10

Werewolf Therapeutics And Ambros Therapeutics Announce Merger; Secure $150M Financing

Werewolf Therapeutics (HOWL) and Ambros Therapeutics announced an all-stock merger, creating a Nasdaq-listed biotech firm focused on neridronate for CRPS-1. The combined company, trading as AMBX, secured $150M in financing. Neridronate has FDA designations and is in Phase 3 trials, with results expected in 2028. The merger values Ambros at $500M and Werewolf at $47.5M, with a planned Q1 2027 close. HOWL shares surged 1431.19% in pre-market trading.